Bendamustine and rituximab in relapsed and refractory hairy cell leukemia

Clinical Cancer Research

Volumn 19, Issue 22, 2013, Pages 6313-6321

  Burotto, Mauricio ^a   Stetler Stevenson, Maryalice ^a   Arons, Evgeny ^a   Zhou, Hong ^a   Wilson, Wyndham ^a   Kreitman, Robert J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CD103 ANTIGEN; CD123 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; GLYCOPROTEIN P 15095; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 2 RECEPTOR ALPHA; RITUXIMAB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CHILL; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEBRILE NEUTROPENIA; FEVER; FOLLOW UP; HAIRY CELL LEUKEMIA; HERPES ZOSTER; HUMAN; HUMAN CELL; HYPERTENSION; LEUKOPENIA; LYMPHOCYTOPENIA; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; TASTE DISORDER; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLOOD PLATELETS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; LEUKEMIA, HAIRY CELL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NITROGEN MUSTARD COMPOUNDS; PILOT PROJECTS; PLATELET COUNT; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84888105753     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-1848     Document Type: Article

References (47)

1. Grever MR, Lozanski G. Modern strategies for hairy cell leukemia. J Clin Oncol 2011;29:583-90.
2. Gidron A, Tallman MS. 2-CdA in the treatment of hairy cell leukemia: a review of long-term follow-up. Leuk Lymphoma 2006;47:2301-7. (Pubitemid 44768422)
3. Else M, Dearden CE, Matutes E, Garcia-Talavera J, Rohatiner AZ, Johnson SA, et al. Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. Br J Haematol 2009;145:733-40.
4. Tallman MS, Hakimian D, Kopecky KJ, Wheaton S, Wollins E, Foucar K, et al. Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse. Clin Cancer Res 1999;5:1665-70. (Pubitemid 29334443)
5. Sigal DS, Sharpe R, Burian C, Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine. Blood 2010;115:1893-6.
6. Sausville JE, Salloum R, Sorbara L, Kingma DW, Raffeld M, Kreitman RJ, et al. Minimal residual disease detection in hairy cell leukemia. Comparison of flow cytometric immunophenotyping with clonal analysis using consensus primer polymerase chain reaction for the heavy chain gene. Am J Clin Pathol 2003;119:213-7. (Pubitemid 37047876)
7. Nieva J, Bethel K, Saven A. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood 2003;102:810-3. (Pubitemid 36917768)
8. Angelopoulou MK, Pangalis GA, Sachanas S, Kokoris SI, Anargyrou K, Galani Z, et al. Outcome and toxicity in relapsed hairy cell leukemia patients treated with rituximab. Leuk Lymphoma 2008;49:1817-20.
9. Forconi F, Toraldo F, Sozzi E, Amato T, Raspadori D, Lauria F. Complete molecular remission induced by concomitant cladribine-rituximab treatment in a case of multi-resistant hairy cell leukemia. Leuk Lymphoma 2007;48:2441-3. (Pubitemid 350253477)
10. Ravandi F, O'Brien S, Jorgensen J, Pierce S, Faderl S, Ferrajoli A, et al. Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia. Blood 2011;118:3818-23.
11. Rummel MJ, Gregory SA. Bendamustine's emerging role in the management of lymphoid malignancies. Semin Hematol 2011;48 Suppl 1:S24-36.
12. Ujjani C, Cheson BD. Bendamustine in chronic lymphocytic leukemia and non-Hodgkin's lymphoma. Expert Rev Anticancer Ther 2010;10:1353-65.
13. Kreitman RJ, Arons E, Stetler-Stevenson M, Miller KB. Response of Hairy Cell Leukemia to Bendamustine. Leuk Lymphoma 2011;52:1153-6.
14. Cheson BD, Rummel MJ. Bendamustine: rebirth of an old drug. J Clin Oncol 2009;27:1492-501.
15. Chow KU, Boehrer S, Geduldig K, Krapohl A, Hoelzer D, Mitrou PS, et al. In vitro induction of apoptosis of neoplastic cells in low-grade non-Hodgkin's lymphomas using combinations of established cytotoxic drugs with bendamustine. Haematologica 2001;86:485-93. (Pubitemid 33638976)
16. Chow KU, Sommerlad WD, Boehrer S, Schneider B, Seipelt G, Rummel MJ, et al. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Haematologica 2002;87:33-43. (Pubitemid 34101111)
17. Fischer K, Cramer P, Busch R, Stilgenbauer S, Bahlo J, Schweighofer CD, et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2011;29:3559-66.
18. Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 2012;30:3209-16.
19. Iannitto E, Morabito F, Mancuso S, Gentile M, Montanini A, Augello A, et al. Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study. Br J Haematol 2011;153:351-7.
20. Rummel MJ, Al-Batran SE, Kim SZ, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005;23:3383-9.
21. Friedberg JW, Vose JM, Kelly JL, Young F, Bernstein SH, Peterson D, et al. The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma. Blood 2011;117:2807-12.
22. Ohmachi K, Niitsu N, Uchida T, Kim SJ, Ando K, Takahashi N, et al. Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2013;31:2103-9.
23. Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822-8.
24. Matutes E. Immunophenotyping and differential diagnosis of hairy cell leukemia. Hematol Oncol Clin North Am 2006;20:1051-63. (Pubitemid 44380352)
25. Shao H, Calvo KR, Grönborg M, Tembhare PR, Kreitman RJ, Stetler-Stevenson M, et al. Distinguishing hairy cell leukemia variant from hairy cell leukemia: development and validation of diagnostic criteria. Leuk Res 2012;37:401-9.
26. Xi L, Arons E, Navarro W, Calvo KR, Stetler-Stevenson M, Raffeld M, et al. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation. Blood 2012;119:3330-2.
27. Kreitman RJ, Wilson WH, White JD, Stetler-Stevenson M, Jaffe ES, Waldmann TA, et al. Phase I trial of recombinant immunotoxin Anti-Tac (Fv)-PE38 (LMB-2) in patients with hematologic malignancies. J Clin Oncol 2000;18:1614-36.
28. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitz Gerald D J P, Wilson WH, et al. Phase II trial of recombinant immunotoxin RFB4 (dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 2009;27:2983-90.
29. Seymour JF, Kurzrock R, Freireich EJ, Estey EH. 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 1994;83:2906-11. (Pubitemid 24142723)
30. Seymour JF, Talpaz M, Kurzrock R. Responseduration and recovery of CD4+lymphocytes following deoxycoformycin in interferon-alpharesistant hairy cell leukemia: 7-year follow-up. Leukemia 1997;11:42-7. (Pubitemid 27065048)
31. Matsushita K, Margulies I, Onda M, Nagata S, Stetler-Stevenson M, Kreitman RJ. Soluble CD22 as a tumor marker for hairy cell leukemia. Blood 2008;112:2272-7.
32. Steis RG, Marcon L, Clark J, Urba W, Longo DL, Nelson DL, et al. Serum soluble IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988;71:1304-9.
33. Knauf WU, Lissitchkov T, Aldaoud A, Liberati AM, Loscertales J, Herbrecht R, et al. Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial. Br J Haematol 2012;159:67-77.
34. Cheson BD, Friedberg JW, Kahl BS, Van der Jagt RH, Tremmel L. Bendamustine produces durable responses with an acceptable safety profile in patients with rituximab-refractory indolent non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2010;10:452-7.
35. Damaj G, Gressin R, Bouabdallah K, Cartron G, Choufi B, Gyan E, et al. Results from a prospective, open-label, phase II trial of bendamustine in refractory or relapsed T-cell lymphomas: the BENTLY trial. J Clin Oncol 2013;31:104-10.
36. Ohmachi K, Ando K, Ogura M, Uchida T, Itoh K, Kubota N, et al. Multicenter phase II study of bendamustine for relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Sci 2010;101:2059-64.
37. Horn J, Kleber M, Hieke S, Schmitt-Graff A, Wasch R, Engelhardt M. Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol 2012;91:1579-86.
38. Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, et al. Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011;22:1839-44.
39. Chacar C, Jabbour E, Ravandi F, Borthakur G, Kadia T, Estrov Z, et al. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome. Clin Lymphoma Myeloma Leuk 2012;12:197-200.
40. Moskowitz AJ, Hamlin PA Jr, Perales MA, Gerecitano J, Horwitz SM, Matasar MJ, et al. Phase II study of bendamustine in relapsed and refractory hodgkin lymphoma. J Clin Oncol 2013;31:456-60.
41. Berenson JR, Yellin O, Bessudo A, Boccia RV, Noga SJ, Gravenor DS, et al. Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. Br J Haematol 2013;160:321-30.
42. Ponisch W, Bourgeois M, Moll B, Heyn S, Jakel N, Wagner I, et al. Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. J Cancer Res Clin Oncol. 2013 Sep. 18. [Epub ahead of print].
43. Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, et al. Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 2012;119:4608-13.
44. Kahl BS, Bartlett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, et al. Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer 2010;116:106-14.
45. Ravandi F, Jorgensen JL, O'Brien S M, Verstovsek S, Koller CA, Faderl S, et al. Eradication of minimal residual disease in hairy cell leukemia. Blood 2006;107:4658-62. (Pubitemid 43882611)
46. Cervetti G, Galimberti S, Andreazzoli F, Fazzi R, Cecconi N, Caracciolo F, et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. Eur J Haematol 2004;73:412-7. (Pubitemid 39564364)
47. Arons E, Margulies I, Sorbara L, Raffeld M, Stetler-Stevenson M, Pastan I, et al. Minimal residual disease in hairy cell leukemia patients assessed by clone-specific polymerase chain reaction. Clin Cancer Res 2006;12:2804-11.